1/23/02
4/18/02
7/16/02
9/12/02

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims.

12. **(Cancelled)**

19. **(Cancelled)**

28. **(Cancelled)**

34. **(Cancelled)**

36. **(Cancelled)**

37. **(Cancelled)**

38. **(Cancelled)**

C1

42. **(Currently Amended)** A method of treating ~~proliferating photoreceptor cells in~~ a patient having an injury to or a degeneration of a photoreceptor cell comprising administering to a patient a therapeutically effective amount of a polypeptide comprising amino acids 108 to 233 of SEQ ID NO:2.

43. **(Previously Added)** The method of claim 42, wherein the polypeptide is attached to a water soluble polymer.

44. **(Previously Added)** The method of claim 43, wherein the water soluble polymer is polyethylene glycol.

45. **(Previously Added)** The method of claim 42, wherein the polypeptide is administered as a pharmaceutical composition.

46. **(Previously Added)** The method of claim 45, wherein the polypeptide pharmaceutical composition is a sustained-release pharmaceutical composition.

47. **(Previously Added)** The method of claim 42, wherein the polypeptide is administered as a topical pharmaceutical composition.

48. **(Previously Added)** The method of claim 42, wherein the polypeptide is administered as an oral pharmaceutical composition.

49. **(Previously Added)** The method of claim 42, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

50. **(Previously Added)** The method of claim 42, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

51. **(Previously Added)** The method of claim 50, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.

52. **(Previously Added)** The method of claim 42, wherein the polypeptide comprises amino acids 80 to 202 of SEQ ID NO:2.

53. **(Previously Added)** The method of claim 52, wherein the polypeptide is attached to a water soluble polymer.

54. **(Previously Added)** The method of claim 53, wherein the water soluble polymer is polyethylene glycol.

C1

55. **(Previously Added)** The method of claim 52, wherein the polypeptide is administered as a pharmaceutical composition.

56. **(Previously Added)** The method of claim 55, wherein the polypeptide pharmaceutical composition is a sustained-release pharmaceutical composition.

57. **(Previously Added)** The method of claim 52, wherein the polypeptide is administered as a topical pharmaceutical composition.

58. **(Previously Added)** The method of claim 52, wherein the polypeptide is administered as an oral pharmaceutical composition.

59. **(Previously Added)** The method of claim 52, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

60. **(Previously Added)** The method of claim 52, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

61. **(Previously Added)** The method of claim 60, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.

62. **(Previously Added)** The method of claim 42, wherein the polypeptide comprises amino acids 9 to 396 of SEQ ID NO:2.

63. **(Previously Added)** The method of claim 62, wherein the polypeptide is attached to a water soluble polymer.

64. **(Previously Added)** The method of claim 63, wherein the water soluble polymer is polyethylene glycol.

65. **(Previously Added)** The method of claim 62, wherein the polypeptide is administered as a pharmaceutical composition.

C1

66. **(Previously Added)** The method of claim 65, wherein the polypeptide pharmaceutical composition is a sustained-release pharmaceutical composition.

67. **(Previously Added)** The method of claim 62, wherein the polypeptide is administered as a topical pharmaceutical composition.

68. **(Previously Added)** The method of claim 62, wherein the polypeptide is administered as an oral pharmaceutical composition.

69. **(Previously Added)** The method of claim 62, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

70. **(Previously Added)** The method of claim 62, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

71. **(Previously Added)** The method of claim 70, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.